ELEVATE (Evaluation of Left Ventricular Autothreshold) 3.0 (ELEVATE 3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01539629
Recruitment Status : Completed
First Posted : February 27, 2012
Last Update Posted : December 5, 2012
Information provided by (Responsible Party):
Boston Scientific Corporation

Brief Summary:
This 3rd phase of the ELEVATE study. The study is collecting data from an implanted CRT-D device to evaluate a new feature for future heart failure devices.

Condition or disease Intervention/treatment
Heart Failure Device: Cardiac pacing

Detailed Description:
ELEVATE 3.0 is an acute, prospective, multicenter feasibility study which is randomized within a patient test sequence and pulse width. The study is designed to characterize the performance of LVAT (Left Ventricular Authothreshold) feature.

Study Type : Observational
Actual Enrollment : 50 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Evaluation of Left Ventricular Autothreshold
Study Start Date : March 2012
Actual Primary Completion Date : June 2012
Actual Study Completion Date : November 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure
U.S. FDA Resources

Group/Cohort Intervention/treatment
Pulse Width
One group reflecting two different pulse widths.
Device: Cardiac pacing
Cadiac pacing via a pulse generator and implaned intracardiac leads.
Other Name: COGNIS PG.

Primary Outcome Measures :
  1. Collect ventricular evoked response signal and CRT-D device data during LV only and Bi-Ventricular voltage step-down pacing. [ Time Frame: Minimum of 24 hrs post CRT-D implant. ]
    The primary objective of this study is to collect real-time signals during LV pacing and voltage step-down from patients with implanted COGNIS devices.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The study population will be a sample of patients with COGNIS CRT-D devices.

Inclusion Criteria:

  • Patients who are age 18 or above, or of legal age to give informed consent specific to state and national law
  • Patients who have a COGNIS CRT-D device implanted for at least 24 hours, with or without an active right atrial lead
  • Patients who have an active LV bipolar or unipolar lead
  • Patients who have an active RV defibrillation lead
  • Patients who are willing and capable of participating in all testing associated with this Clinical Investigation

Exclusion Criteria:

  • Patients who have a COGNIS CRT-D that has less than or equal to one year of battery life remaining
  • Patients who are pacemaker-dependent as defined as VVI 40 without intrinsic atrial or ventricular activity
  • Patients who will not tolerate a pacing pause of up to 6 seconds
  • Patients with a pre-existing unipolar pacemaker
  • Patients who are unable or unwilling to maintain a supine or sitting position for 20-50 minutes
  • Patients enrolled in any concurrent study, without Boston Scientific CRM written approval
  • Women who are pregnant;women of childbearing potential must have a negative pregnancy test within 7 days prior to enrollment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01539629

United States, Iowa
Genesis Medical Center
Davenport, Iowa, United States, 52803
United States, Pennsylvania
Cardiology Consultants of Philadelphia
Yardley, Pennsylvania, United States, 19067
United States, Virginia
Virginia Commonwealth University Health System
Richmond, Virginia, United States, 23298-0053
United States, Wisconsin
Wheaton Franciscan Health Care
Wauwatosa, Wisconsin, United States, 53226
Sponsors and Collaborators
Boston Scientific Corporation
Principal Investigator: Kenneth L Ellenbogen, MD Virginia Commonwealth University Health System

Responsible Party: Boston Scientific Corporation Identifier: NCT01539629     History of Changes
Other Study ID Numbers: ELEVATE 3.0
First Posted: February 27, 2012    Key Record Dates
Last Update Posted: December 5, 2012
Last Verified: October 2012

Keywords provided by Boston Scientific Corporation:
Heart failure
CRT-D recipients
Left Ventricular evoked response signals

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases